drugset
drugset / Trial / NCT06551584

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

NCT06551584 ↗

Phase 1 Recruiting 24 enrolled Stanford University Incyte Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

Timeline

Start
2025-12-01
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Orca-T Cell therapy — —

Indications

acute lymphoblastic leukemia mixed phenotype acute leukemia myelodysplastic syndrome